First neurosurgical robot installation in Saudi Arabia

Renishaw's neuromate® has received marketing authorisation for sale in the Kingdom of Saudi Arabia by the Saudi Food and Drug Authority

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Working with Renishaw to bring in the neuromate to Saudi Arabia is consistent with Gulf Medical’s long history of introducing proven medical innovations into the kingdom.

(PRWEB UK) 3 March 2014

Renishaw is pleased to announce that its stereotactic neurosurgical robotic system, neuromate®, has received marketing authorisation for sale in the Kingdom of Saudi Arabia by the Saudi Food and Drug Authority. A neuromate system has recently been installed and the first surgical procedures have been performed at the King Fahad Medical City Hospital in Riyadh. This is the first placement of a neurosurgical robot in the Kingdom of Saudi Arabia.

Prof. Mahmoud al Yamany, Chief Executive Officer of King Fahad Medical City, a Neurosurgeon by training, said,
“The newly acquired neuromate system will provide our neurosurgical team with cutting-edge robotic technology that enables the surgeons to deliver neuro-implantable devices with the highest accuracy. We are excited about the new possibilities we have with a neurosurgical robot in our operating room, and are pleased to be the first center in Saudi Arabia to offer robotic neurosurgery to our patients.”

Dr Ismail Ahmed, President of Gulf Medical said;
“Working with Renishaw to bring in the neuromate to Saudi Arabia is consistent with Gulf Medical’s long history of introducing proven medical innovations into the kingdom.”

Dr. Abed Hammoud, CEO of Renishaw Mayfield SA said;
“We are proud of this newest installation in Saudi Arabia. Yet another team of leading neurosurgeons has chosen the neuromate system and Renishaw as a partner in the neurosurgical operating room.”

The neuromate is in use at many leading neurosurgical centers around the world, with France having the largest installed base (with 7 units currently in use). The neuromate has been cited in more than 30 published peer-reviewed scientific journal articles.

Renishaw is a global company with core skills in measurement, motion control, spectroscopy, neurosurgical products and precision machining. The company has 3,300 employees based at offices in 32 countries, and is listed on the London Stock Exchange (LSE:RSW) where it is a constituent of the FTSE 250.

For more information visit http://www.renishaw.com